Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
about
Leflunomide: mode of action in the treatment of rheumatoid arthritisThe active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytesChronic Renal Transplant Rejection and Possible Anti-Proliferative Drug TargetsOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionHigh-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr micePlasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.New oral disease-modifying therapies for multiple sclerosis.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.Oral disease-modifying therapies for multiple sclerosis.Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export.Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenaseRole of oral teriflunomide in the management of multiple sclerosis.Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.An update of teriflunomide for treatment of multiple sclerosis.Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.Effects of leflunomide on inflamation and fibrosis in bleomycine induced pulmonary fibrosis in wistar albino rats.Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.AHR-mediated immunomodulation: the role of altered gene transcription.Leflunomide: dermatologic perspective.Emerging oral drugs for relapsing-remitting multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Fluorescence assay of dihydroorotate dehydrogenase that may become a cancer biomarkerNovel Diketopiperazine Dihydroorotate Dehydrogenase Inhibitors Purified from Traditional Tibetan Animal Medicine Osteon Myospalacem Baileyi.Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy.The two sides of a lipid-protein story.Immunomodulatory properties of S- and N-alkylated 5-(1H-indol-2-yl)-1,3,4-oxadiazole-2(3H)-thione.Teriflunomide for oral therapy in multiple sclerosis.Syntheses of 3-acetoacetylaminobenzo[b]furan derivatives having cysteinyl leukotriene 2 receptor antagonistic activity.Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenasePyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases
P2860
Q24675005-653E9E1F-46F3-450B-90EC-3590FD04F68FQ24800491-BD042BD9-2627-4298-A343-D602144147C0Q26775103-5406DB88-651E-49A2-8933-3EB345D3C1D6Q26822611-18A63ACA-AC99-4707-BA12-F6C6A9121CD2Q31156888-14DE247E-E274-494C-B814-95CB8F4C787FQ33614540-5EE80CBF-1B0F-4B2B-998F-8639251A4CA3Q33723154-BB4F5017-7C88-409A-A0B3-31A0C97537BDQ33844680-F1991D07-7140-4FB7-BCF4-7BD7596CBCF7Q33882490-452225B0-5820-471B-9425-C522C7F2E66CQ33903812-ECB37A1D-6064-4549-BF51-58EE8CEB158AQ34076398-D39D2A5B-1145-4C9A-8F6B-AFA3E0E755B0Q34389332-432364F3-A77B-41D7-A5CD-ED9C879AF355Q34805086-DDDFEFA9-70D4-4CBD-A5E1-740066F6098CQ34996562-C2E2F342-26F2-45A6-A6C4-16A52825AC26Q35015845-CC1708C8-5F97-4D0C-95E9-1D62A1BBD7DAQ35552561-785D0099-ECBD-45DB-BC06-059B120E3155Q35744520-E713682F-78E3-4182-837B-6E78BF62C9ECQ35828195-6926F9DA-DBB1-4CC8-B03C-2135CDEFDFD3Q36247004-B44E4387-83FA-4195-B68F-6A90B14A7DE6Q36803649-159CB89D-B416-41C8-A97C-45CF2517279EQ36887749-49BD7AA6-4553-4562-B3B3-B780F4B4A4A1Q36906008-B63E90E2-74E8-4593-BA2D-4BA5A7F7B762Q37057973-BFF2F989-A511-409C-B80E-F4404F980A01Q37159817-A25F1BB1-8A79-452D-8F31-186E60FEECC4Q37274585-1C976600-9A5C-411B-8CA9-567E561D97D6Q37348966-8259EAEF-D67E-4A5C-9BEA-2E12BE9563A9Q37355946-1224AFA5-57ED-46DA-B650-DD803E6D0A71Q37908152-83BEC821-1C8F-4EFB-9227-F387FD7D0FCFQ37965547-26F2EDD4-D7D4-4B8D-8D07-2C7D37E9108EQ38117110-2C2D3730-545E-482E-A2DC-89ED473BDA21Q38697262-17AC8EFC-EC36-426F-834C-D7545FC7072FQ39022610-45C69482-C1AA-4362-A740-19E9D9DB302BQ39048041-317CF4CD-3103-460C-8F23-E1DC4C3C3753Q39104459-D1C0F4AB-3B7D-4315-9CCF-EFDDE79CF8E3Q39310476-D98F1049-16F7-454C-9BD2-7E5A3240C2AAQ39432434-A23F27F8-06D4-4865-9D16-1BFE21255734Q39504360-5C87BB7D-BC81-418A-93CF-8F2A837D2334Q40591040-4E4CF0DB-0BC7-4D47-92E6-ABF031E4D24FQ41176096-FC9B1450-5A28-4DE5-8977-4D5DC0F74B8EQ41459340-0DA40C2D-18A4-452D-9290-68798D7158C3
P2860
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@ast
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@en
type
label
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@ast
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@en
prefLabel
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@ast
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@en
P2093
P1433
P1476
Leflunomide: an immunomodulato ...... and other autoimmune diseases.
@en
P2093
Herrmann ML
Kirschbaum BJ
Schleyerbach R
P304
P356
10.1016/S0162-3109(00)00191-0
P577
2000-05-01T00:00:00Z